← signals
2026-08-05·OPENAI·hyperscaler internal chip
lowup

As of 2026-08-05, prediction-market consensus on Manifold Markets signals a strong market belief that OpenAI will...

As of 2026-08-05, prediction-market consensus on Manifold Markets signals a strong market belief that OpenAI will pursue internal custom silicon: 93.15% yes on designing and manufacturing a custom AI chip by 2030 (source 2).

window 90devidence 13confidence score 91

confidence score

Strong evidence: 1 independent source class support this read.

91
low confidence1 independent source classesmarketpasses publish gate

signal brief

As of 2026-08-05, prediction-market consensus on Manifold Markets signals a strong market belief that OpenAI will pursue internal custom silicon: 93.15% yes on designing and manufacturing a custom AI chip by 2030 (source 2). The same platform shows only 24.71% expectation that OpenAI will publicly share its multi-provider chip software in 2026 (source 1), and only 10.83% expectation that OpenAI will sell/rent AI compute to external customers by end-2026 (source 13). Taken together, these odds imply market participants expect OpenAI's chip work to remain an internal, vertically-integrated effort rather than a merchant silicon/compute business. For AI-infrastructure watchers, this points to OpenAI deepening its own silicon roadmap, with potential long-term implications for NVIDIA, TSMC, and custom ASIC partners, even though no official announcement has been made. The signal is low confidence because it is derived from speculative prediction-market prices, not corporate filings or confirmed supply-chain events.

What the sources said:

  • "Will OpenAI design and manufacture a custom AI chip by 2030? YES=93.15%" (source 2)
  • "Will OpenAI publicly share software it developed to make its AI run on chips from different providers, in 2026? YES=24.71%" (source 1)
  • "OpenAI sells/rents AI compute to external customers by end-2026? YES=10.83%" (source 13)

source data used

Decision support, not stock advice. This signal is research with cited evidence — not a recommendation to buy, sell, or hold any security.